Induction of myeloproliferative disorder and myelofibrosis by thrombopoietin receptor W515 mutants is mediated by cytosolic tyrosine 112 of the receptor

Ligand-independent Thrombopoietin Mutant Receptor Requires Cell Surface Localization for Endogenous Activity

(2009) Caroline Marty et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Activating mutations in human acute megakaryoblastic leukemia

(2008) S. Malinge et al.   BLOOD

YRRL motifs in the cytoplasmic domain of the thrombopoietin receptor regulate receptor internalization and degradation

(2008) I. S. Hitchcock et al.   BLOOD

Selective Inhibition of JAK2-Driven Erythroid Differentiation of Polycythemia Vera Progenitors

(2008) Ifat Geron et al.   CANCER CELL

Efficacy of TG101348, a Selective JAK2 Inhibitor, in Treatment of a Murine Model of JAK2V617F-Induced Polycythemia Vera

(2008) Gerlinde Wernig et al.   CANCER CELL

Characterization of 35 new cases with four different MPLW515 mutations and essential thrombocytosis or primary myelofibrosis

(2008) S. Schnittger et al.   HAEMATOLOGICA

Effects of the JAK2 Inhibitor, AZ960, on Pim/BAD/BCL-xL Survival Signaling in the Human JAK2 V617F Cell Line SET-2

(2008) Joseph M. Gozgit et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G1/S-phase transition

(2008) R Chaligné et al.   LEUKEMIA

From the first protein structures to our current knowledge of protein folding: delights and scepticisms

(2008) Alan R. Fersht   NATURE REVIEWS MOLECULAR CELL BIOLOGY